HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

NCT03685331 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Locally Advanced Breast Cancer
Advanced Breast Cancer
BRCA2 Mutation
BRCA1 Mutation

Interventions

DRUG: Palbociclib
DRUG: Olaparib
DRUG: Fulvestrant

Sponsor

Abramson Cancer Center at Penn Medicine